March 09, 2010

Update on Federal Enforcement of MedTech Industry & Issues For Emerging companies

Update on Federal Enforcement of MedTech Industry & Issues For Emerging Companies.

Overview

Washington, D.C., partner Jesse Witten spoke to the Bay Area Life Sciences Inhouse Lawyers Group on March 9, 2010, in Palo Alto, California. Jesse’s presentation, “Update on Federal Enforcement of MedTech Industry & Issues For Emerging companies,” covered recent government investigations and qui tam enforcement actions alleging off-label promotion, violations of the Anti-Kickback Statute and the Foreign Corrupt Practices Act, and failure to report adverse events, among other things. The group discussed issues of special significance to emerging companies, such as enforcement and compliance risks in the context of clinical trials and medical research.

Services and Industries

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.